Next-generation vaccines—eliminating the use of needles
Lead scientist Professor Simon Cutting, from the School of Biological Sciences at Royal Holloway, has developed the jabs through the use of probiotic spores. He carried out fundamental studies into the biology of the bacterium Bacillus subtilis which attracted the attention of microbiologists due to its ability to form spores that can last millions of years before germinating under the appropriate environmental conditions.
Professor Cutting says: "The mechanisms by which this process occurs have fascinated microbiologists for decades making it one of the most intensively studied bacteria. Its simple life cycle and ease of use make it an ideal laboratory subject."
Professor Cutting discovered that the Bacillus spores act as ideal vehicles to carry antigens and promote an immune response. He explains: "Rather than requiring needle delivery, vaccines based on Bacillus spores can be delivered via a nasal spray, or as on oral liquid or capsule. Alternatively they can be administered via a small soluble film placed under the tongue, in a similar way to modern breath freshners. As spores are exceptionally stable, vaccines based on Bacillus do not require cold-chain storage alleviating a further issue with current vaccine approaches."
As well as eliminating the pain associated with needles, oral vaccines provide greater benefits including being safer to administer, especially in developing countries where HIV is rife, being inexpensive to produce and easier to store and reducing concerns of adverse reactions.
Professor Cutting has carried out pre-clinical evaluation of Bacillus-based vaccines for a number of diseases including Tuberculosis, influenza and tetanus but most recently he has been investigating the potential for use of the vaccines against a disease of particular relevance to the West - Clostridium difficile
"C. difficile, is a gastrointenstinal infection that is commonly picked up following hospital stays and causes around 50,000 infections and 4,000 deaths per year in the UK, mostly in elderly patients. Currently, there is no vaccine against the disease, and although several approaches are currently undergoing clinical trials, none are expected to provide full protection, and new solutions are urgently needed," says Professor Cutting.
He adds: "Bacillus based vaccines offer distinct advantages as unlike other approaches, oral delivery can cause a more specific immune response in the gastrointenstinal tract to fully eliminate C.difficile."
Professor Cutting has recently received private seed investment to form a company, Holloway Immunology, to develop the bacillus vaccine technology and concentrate on three lead vaccines for Tuberculosis, C. difficile infection and influenza (flu). The company is currently looking for investors to help fast track the implementation of these jabs and contribute to the transformation of vaccine delivery around the globe.
Provided by Royal Holloway, University of London
- Better vaccines for tuberculosis could save millions of lives Aug 28, 2012 | not rated yet | 0
- Anthrax capsule vaccine protects monkeys from lethal infection Jan 12, 2012 | not rated yet | 0
- New low-cost method to deliver vaccine shows promise Nov 16, 2010 | not rated yet | 0
- Inhaled tuberculosis vaccine more effective than traditional shot Mar 12, 2008 | not rated yet | 0
- New tuberculosis vaccine is developed Jun 06, 2007 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications 19 hours ago | 5 / 5 (1) | 0
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications 20 hours ago | not rated yet | 0
(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...
Medications May 20, 2013 | 5 / 5 (1) | 0
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications May 17, 2013 | not rated yet | 0
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications May 17, 2013 | 5 / 5 (1) | 1
(HealthDay)—Injections of a sugar solution appear to help relieve knee pain and stiffness related to osteoarthritis, a new study suggests.
27 minutes ago | not rated yet | 0 |
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...
35 minutes ago | not rated yet | 0 |
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...
30 minutes ago | not rated yet | 0 |
(HealthDay)—Obese and overweight men and women who suffer from heartburn often report relief when they lose weight, a new study shows.
17 minutes ago | not rated yet | 0 |
(HealthDay)—When it comes to the care of your children's teeth, dentists aren't the only experts who can help.
37 minutes ago | not rated yet | 0
(HealthDay)—For patients with acute respiratory distress syndrome (ARDS), prolonged prone positioning during mechanical ventilation is associated with significantly reduced mortality at 28 and 90 days, ...
57 minutes ago | not rated yet | 0